Work

Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC)

Year: 2022

Type: article

Source: Journal of Investigative Dermatology

DOI: 10.1016/j.jid.2022.08.004

Authors: Varsha Ananthapadmanabhan, Thomas C. Frost, Kara M. Soroko, Aine Knott, Brianna Magliozzi, Prafulla C. Gokhale, Vijaya Tirunagaru, Robert C. Doebele, James A. DeCaprio

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4296641484

FWCI:

Cites:

Cited by:

Related to: 10